Physician profile
Shawn Patrick Millison
NPI 1477122174
$1,273.10
in general payments reported to CMS, 2019-2025
19 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.76 · 2022: $373 · 2023: $237 · 2024: $217 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $198.72 | 2025 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $144.42 | 2022-2025 | Airsupra, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $144.06 | 2022 | |
| Pfizer INC. | $130.76 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $88.48 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.24 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $75.75 | 2022-2023 | Trintellix |
| Glaxosmithkline, LLC. | $73.68 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Sunovion Pharmaceuticals INC. | $65.01 | 2021-2022 | |
| Exact Sciences Corporation | $47.48 | 2024 | Cologuard Collection Kit |
| Indivior INC. | $47.25 | 2023-2024 | Sublocade, Perseris |
| Novo Nordisk INC | $35.93 | 2021-2022 | |
| Lilly USA, LLC | $34.67 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $25.47 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.14 | 2023 | Xifaxan, Trulance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.58 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $12.78 | 2022 | |
| Sumitomo Pharma America, INC. | $11.94 | 2023 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Millison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.